09th week of 2014 patent applcation highlights part 36 |
Patent application number | Title | Published |
20140056810 | CONJUGATES AND THEIR USES IN MOLECULAR IMAGING - The present invention relates to bifunctional compounds, the bifunctional compounds for use in molecular imaging and therapy, methods of molecular imaging using the bifunctional compounds and kits including the bifunctional compounds for use molecular imaging. The bifunctional compounds have a tripodal hydroxypyridinone chelating portion and may be conjugated to a targeting group so that the compounds target specific cells or tissues in a subject. | 2014-02-27 |
20140056811 | NEW CELL-PENETRATING PEPTIDES AND USES THEREOF - The present invention is related to peptides, which are suitable for use as cell-penetrating peptides (CPPs), variants thereof and/or complexes, fusion molecules and/or conjugates comprising same, use thereof for manufacture of compositions for diagnosing, treating and/or preventing of medical conditions. | 2014-02-27 |
20140056812 | Imaging Beta Cell Mass - The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass. | 2014-02-27 |
20140056813 | NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF - The present application relates to thermosensitive liposomes encapsulating nanoparticles which can be used in the health sector, in particular in human health. The invention also relates to pharmaceutical and diagnostic compositions comprising thermosensitive liposomes as defined previously, as well as to their uses. | 2014-02-27 |
20140056814 | METHOD OF CONSTRUCTING ANIMAL HAVING CANCER CELLS TRANSPLANTED THEREINTO - A cell culture support is first prepared that is coated on a surface with a polymer the hydration force of which changes in a temperature range of 0-80° C.; cancer cells are then cultivated on the support in a temperature region where the polymer has weak hydration force; thereafter, the culture solution is adjusted to a temperature at which the polymer has a stronger hydration force, whereby the cultured cancer cells are detached; the detached cancer cells are then transplanted to a specified site of an animal on which transplantation is to be performed; this method is an efficient way of cancer cells transplantation. | 2014-02-27 |
20140056815 | METHODS TO REGULATE POLARIZATION AND ENHANCE FUNCTION OF CELLS - Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells. | 2014-02-27 |
20140056816 | IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS - Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation. | 2014-02-27 |
20140056817 | PHOTODYNAMIC THERAPY OR DIAGNOSTIC AGENT, USING INFRARED-SPECTRUM LIGHT - It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 μm to 2.5 μm; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group. | 2014-02-27 |
20140056818 | PROCESS FOR DELIVERING ENCAPSULATED NEUTRAL BIOIMAGING MOLECULES, COMPLEX, AND PROCESS THEREOF - The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral DNA capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like FITC dextran within the cavity of a DNA polyhedron without any molecular recognition or chemical conjugation between host (DNA icosahedron) and cargo (like FITC Dextran). This DNA polyhedron is structurally well defined and shows high encapsulation efficiency. The present disclosure also relates to complex formed due to the encapsulation of neutral bioimaging agents within icosahedral DNA capsules. | 2014-02-27 |
20140056819 | NANOPARTICULATE COMPOSITIONS FOR DIAGNOSTIC IMAGING - The present invention provides a trialkoxysilanes having structure I | 2014-02-27 |
20140056820 | TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from | 2014-02-27 |
20140056821 | NANOPARTICULATE COMPOSITIONS FOR DIAGNOSTIC IMAGING - The present invention provides a trialkoxysilane having structure I | 2014-02-27 |
20140056822 | DNA Dendrimers as Thermal Ablation Devices - DNA dendrimers for targeted delivery of radiation absorbing nanoparticles and thermal ablation of cells and tissues are provided. Also provided are methods of making and methods of using the DNA dendrimers. | 2014-02-27 |
20140056823 | COMBINATIONS OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - A pharmaceutical composition comprising:
| 2014-02-27 |
20140056824 | IONIC COMPLEXES - The present invention provides a phosphopeptide or phosphoprotein (PP) stabilised amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion greater than about 30 moles of calcium per mole of PP. | 2014-02-27 |
20140056825 | FUNCTIONAL FRAGRANCE PRECURSOR - The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being of the formula X—O—C(R)(R*)(OR**) wherein R is a C | 2014-02-27 |
20140056826 | FUNCTIONAL FRAGRANCE PRECURSOR - The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being, of the formula X—O—C(R)(R*)(OR**) wherein R is a C | 2014-02-27 |
20140056827 | DENTAL COMPOSITION - Aqueous homogeneous oral care compositions including a fluoride salt and unfunctionalised β-tricalcium phosphate, characterised in that β-tricalcium phosphate is present in a catalytic and fluoride-stable amount relative to the fluoride salt. Such compositions are of use in combating dental caries, dental erosion and/or tooth wear. | 2014-02-27 |
20140056828 | NOVEL FORMULATIONS AND USES FOR CURCUMA EXTRACTS - Formulations and uses of extracts of | 2014-02-27 |
20140056829 | SUNSCREEN COMPRISING A CURCUMA EXTRACT - Sunscreen compositions containing an extract of | 2014-02-27 |
20140056830 | METHOD OF PRODUCING A SAFE, WHOLE-EXTRACT OF CURCUMA FOR ORAL AND TOPICAL USE - Methods of making safe extracts of | 2014-02-27 |
20140056831 | Treatment and Reduction in Incidence of Skin Cancer - A method for treatment of skin cancer in tissue within the skin of a mammal uses the ingestion, injection, infusion or application of an ingredient having a pharmaceutically active phenyl boric acid or salts of a phenyl boric acid to treat the affected tissue. The treatment may be with an amount of ingredient that inhibits the growth of at least one cancer cell line selected from basal cell carcinoma skin lines, and squamous cell carcinoma skin lines and melanoma skin cell lines. | 2014-02-27 |
20140056832 | USE OF A 2-METHYLSUCCINIC ACID DIESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS CONTAINING THE SAME - The present invention relates to the use of at least one 2-methylsuccinic acid diester derivative of formula (I), in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, for dissolving the said active agent in the said liquid fatty phase and/or for improving the solubility of the said active agent in the said solid fatty phase. The present invention relates especially to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it contains at least one 2-methylsuccinic acid ester derivative of formula (I) and at least one lipophilic active agent. | 2014-02-27 |
20140056833 | Compositions and methods for nail coatings - The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions and adhesion-promoting basecoats polymerized therefrom. The disclosure further relates to methods of making a polymerized basecoat that are more easily removed than artificial nail enhancements and more durable and long lasting than nail polish coatings. | 2014-02-27 |
20140056834 | COSMETIC COMPOSITION COMPRISING CHRYSOPHANOL AS ACTIVE INGREDIENT FOR SKIN WHITENING - A novel use of chrysophanol for skin whitening is provided, in which chrysophanol is included in a cosmetic composition as an effective ingredient for skin whitening. The chrysophanol compound has excellent stability and can also effectively inhibit melanin production via mechanism of inhibiting expression and activity of tyrosinase. | 2014-02-27 |
20140056835 | COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING SMALL MOLECULE-PEPTIDE CONJUGATE - The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH | 2014-02-27 |
20140056836 | Spray-Dried Compositions and Their Uses - The present invention relates to spray dried compositions of one or more active ingredients dispersed in a carrier of gum Arabic in admixture with a non-ionic surfactant. The compositions are particularly useful for the encapsulation of menthol and can be used to prepare chewing gums and compressed tablets. | 2014-02-27 |
20140056837 | COMPOSITIONS AND METHODS FOR CONTROL OF MALODOR AND OTHER ENVIRONMENTAL CONTAMINANTS - Nanocomposite compositions forming mixed clathrates and methods for using such compositions for entrapping guest moieties such as malodors, molds and cells are disclosed. | 2014-02-27 |
20140056838 | Recreational Water with Improved Interaction with Skin, Hair and Eyes - The feel of skin and hair and the manageability of hair exposed to recreational water is improved by the addition of select organic polymers, e.g., charged organic polymers such as cationic organic polymers containing multiple charges. In one embodiment, excellent results are achieved when the added organic polymer(s) include polymeric quaternary ammonium compounds such as poly-DADMAC. The cationic organic polymers of the invention do not interfere with the activity of other recreational water treatments such as halogen releasing compounds and do not decompose due to the presence of halogen releasing water sanitizers, generate a detectable odor or impart noticeable color to the recreational water. | 2014-02-27 |
20140056839 | METHODS FOR SEALING WOUNDS WITH A STERILIZED COMPOSITION OF A CYANOACRYLATE MONOMER AND A POLOXAMER - The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field. | 2014-02-27 |
20140056840 | HINDERED ALKYLAMINE POLYMER - The present invention relates to a polymer comprising hindered primary amine groups bonded to the backbone of the polymer by way of an amide, ester, or thioester linkage. The polymer is particularly useful as an adjuvant, especially for isothiazolone, and as a dispersant and stain blocker in coatings formulations. | 2014-02-27 |
20140056841 | Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms - Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value. Some of the compositions are also provided for inclusion into a device for preventing infection, reducing inflammation, and preserving the activity of a protein or protein drug. | 2014-02-27 |
20140056842 | CELLULAR THERAPEUTIC APPROACHES TO TRAUMATIC BRAIN AND SPINAL CORD INJURY - The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4 cells that have CXCR-4-mediated chemotactic activity. | 2014-02-27 |
20140056843 | TNFSF SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 2014-02-27 |
20140056844 | METHODS OF METABOLIC TARGETING CANCER CELLS USING CHEMO- AND IMMUNOTHERAPY FOR TREATING CANCER - Methods for treating cancer comprising administering a metabolic targeting chemo-immunotherapy regimen are provided herein. In one embodiment, the metabolic targeting chemo-immunotherapy regimen may include steps of administering a therapeutically effective dose of one or more immunologic agents (e.g., a therapeutic antibody) to stimulate an immune response in a subject having cancer; reducing the patient's blood glucose level; and administering a therapeutically effective dose of one or more chemotherapeutic agents. The methods described herein may be used to treat any type of cancer, especially malignant and metastatic late stage cancers. | 2014-02-27 |
20140056845 | Method for Generating Potent Dendritic Cells - Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32. | 2014-02-27 |
20140056846 | Treating Hepatitis C Virus Infection - Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person. | 2014-02-27 |
20140056847 | INHIBITORS OF SERINE PROTEASES - This invention relates to compounds of formula I: | 2014-02-27 |
20140056848 | Method for the Treatment of Multiple Sclerosis - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof. | 2014-02-27 |
20140056849 | SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE - The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer. | 2014-02-27 |
20140056850 | DICTYOSTELID AMOEBA AND BIOCONTROL USES THEREOF - The present invention relates to Dictyostelids myxamoebae of phylum Mycetozoa and uses thereof. In particular, the present invention relates to the use of amoebae, slugs, or their environmentally stable spores to treat microbial infections and other uses. | 2014-02-27 |
20140056851 | METHODS FOR MANAGING WEIGHT LOSS AND BODY MASS - The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal preventing a reduction in energy metabolism by an animal reducing the risk of regaining weight by an animal after weight loss, and ameliorating undesirable animal behaviors associated with reduced caloric intake by intermittently feeding an animal a first diet containing calories that meet the animal's maintenance energy requirements and a second diet containing calories that do not meet the animal's maintenance energy requirements. In preferred embodiments, the described feeding pattern and diets are ted in conjunction with one or more weight loss agents. | 2014-02-27 |
20140056852 | BIFIDOBACTERIUM BIFIDUM STRAINS FOR APPLICATION IN GASTROINTESTINAL DISEASES - The present invention provides a strain of | 2014-02-27 |
20140056853 | Compositions and Methods for Modulating Plant Parasitic Nematodes - Provided is a method for modulating soybean cyst nematode infestation of a plant comprising applying to the plant an effective amount of a composition comprising a | 2014-02-27 |
20140056854 | VIRAL VECTORS WITH MODIFIED TRANSDUCTION PROFILES AND METHODS OF MAKING AND USING THE SAME - The present invention provides AAV capsid proteins, virus capsids comprising said capsid proteins and virus vectors comprising said capsid proteins, wherein the AAV capsid proteins have one or more mutations, wherein the mutation(s) result in a phenotype of decreased liver transduction and/or reduced glycan binding affinity as compared to a control. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject. | 2014-02-27 |
20140056855 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT - The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α | 2014-02-27 |
20140056856 | IMMUNOSUPPRESSIVE CELLS AND METHODS OF MAKING AND USING THEREOF - This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine. | 2014-02-27 |
20140056857 | Cancellous Bone Treated with Collagenase and Essentially Free of Blood Cells - A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying our their osteogenic function and to provide for an increased rate of bone formation. | 2014-02-27 |
20140056858 | CELL SHEET HAVING HYALURONIC ACID PRODUCTION ABILITY AND METHOD FOR PREPARING THE SAME - A cell sheet having a high hyaluronic acid production ability can be typically prepared by a method in which, on a cell culture support having a surface coated with a polymer which changes a hydration ability in a temperature range of 0-80° C., cells with increased stem cell content are cultured in a temperature range where the polymer exhibits a weak hydration ability, and then the temperature of a culture solution is changed to a temperature at which the polymer exhibits a strong hydration ability, so that the cultured cells are detached in the form of sheet. | 2014-02-27 |
20140056859 | METHOD FOR PRODUCING MYOCARDIAL SHEET FROM EMBRYONIC STEM CELLS - The present invention provides a method for producing a myocardial sheet using a group of cells derived from embryonic stem cells. This method is characterized by mixing Flk/KDR positive cells, cardiomyocytes, endothelial cells, and mural cells, all derived from embryonic stem cells, and culturing the mixed cells. Furthermore, the myocardial sheet can be used as a therapeutic agent for heart diseases since VEGF is released from the sheet. | 2014-02-27 |
20140056860 | METHOD FOR REJUVENATING CELLS - The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog. | 2014-02-27 |
20140056861 | RECOMBINANT FACTOR VIII HAVING INCREASED STABILITY - The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule. | 2014-02-27 |
20140056862 | NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND ALPHA-KETOGLUTARATE - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid and α-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-27 |
20140056863 | NUTRITIONAL COMPOSITIONS HAVING ALPHA-HICA AND EICOSAPENTAENOIC ACID - Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include α-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, α-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided. | 2014-02-27 |
20140056864 | BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS AND VIRUS TRANSMISSION - Methods of inducing systemic acquired resistance to infection in a plant are provided. The methods comprise applying a composition comprising a | 2014-02-27 |
20140056865 | ADIPOSE COMPOSITION SYSTEMS AND METHODS - Embodiments of the present invention encompass compositions containing an adipose derived carrier, matrix, or filler, in some cases optionally in combination with bone particles or other granular materials or substances, for delivery to a human patient. Methods of manufacture and use of such adipose derived compositions are also disclosed. | 2014-02-27 |
20140056866 | USE OF BIOLOGICAL OR CHEMICAL CONTROL AGENTS FOR CONTROLLING INSECTS AND NEMATODES IN RESISTANT CROPS - The present invention relates generally to the use of biological or chemical control agents with for controlling insects and nematodes and to methods particularly useful for combating insects or nematodes and/or increasing crop yield in plants that are at least partially resistant to one or more parasitic nematodes or insects. | 2014-02-27 |
20140056867 | TARGETED THERAPEUTIC PROTEINS - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 2014-02-27 |
20140056868 | Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement - In some embodiments the present disclosure provides a composition for targeted alteration of a DNA sequence and methods of altering the targeted DNA sequence using the composition. In some embodiments such a composition comprises a MiniVector comprising a nucleic acid sequence template for homology-directed repair, alteration, or replacement of the targeted DNA sequence within a cell in vivo or in vitro, where the MiniVector lacks both a bacterial origin of replication and an antibiotic selection gene, and wherein the MiniVector has a size up to about 2,500 base pairs. In further embodiments of the present disclosure the nucleic acid sequence template for the homology-directed repair, alteration, or replacement of the targeted DNA sequence comprises at least one portion of the template complementary to a nucleic acid sequence near the targeted DNA sequence to be altered; and at least one portion of the template which is not complementary to the targeted DNA sequence to be altered, wherein the non-complementary portion of the nucleic acid template contains the alteration desired in the targeted DNA sequence. In some embodiments, the composition further comprises at least one site-specific nuclease. Further embodiments of the present disclosure pertain to a method of treating a genetic disorder, or other condition, in a subject in need thereof. | 2014-02-27 |
20140056869 | Compositions and Methods for Enhancing Metal Ion Dependent Drug Therapies - Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers. | 2014-02-27 |
20140056870 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which cleaves a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that binds a Binding Site on the nociceptive sensory afferent, which can undergo endocytosis to be incorporated into an endosome; a protease cleavage site where the fusion protein is cleavable by a protease located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that translocates the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer from 4 to 25 amino acids between the non-cytotoxic protease and protease cleavage site; and a second spacer comprising from 4 to 35 residues between the galanin Targeting Moiety and translocation domain. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 2014-02-27 |
20140056871 | ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR - The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders. | 2014-02-27 |
20140056872 | ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF - The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. | 2014-02-27 |
20140056873 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2014-02-27 |
20140056874 | METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2014-02-27 |
20140056875 | METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2014-02-27 |
20140056876 | METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2014-02-27 |
20140056877 | Stabilized Liquid Anti-RSV Antibody Formulations - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. | 2014-02-27 |
20140056878 | HUMANIZED ANTIBODIES DIRECTED AGAINST COMPLEMENT PROTEIN C5 - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to complement protein C5. The invention provides a C5-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention provides an isolated complement protein C5 epitope. The invention also provides related vectors, compositions, and methods of using the C5-binding agent to treat an C5-mediated disease. | 2014-02-27 |
20140056879 | FC VARIANTS THAT EXTEND ANTIBODY HALF-LIFE - The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody. | 2014-02-27 |
20140056880 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS - The present invention provides triazole compounds of Formula I: | 2014-02-27 |
20140056881 | METHOD AND KIT FOR THE DETECTION OF GENES ASSOCIATED WITH PIK3CA MUTATION AND INVOLVED IN PI3K/AKT PATHWAY ACTIVATION IN THE ER-POSTITIVE AND HER2-POSITIVE SUBTYPES WITH CLINICAL IMPLICATIONS - A method to determine the clinical outcome of breast tumour affecting a patient if treated with an antitumoural agent against breast tumour, the said method comprising the step of assaying a sample of a breast tumour from said patient for an expression level of selected genes, by contacting mRNA sequences from the cells of this breast tumour with a set of more than 3 nucleotide sequences related to human mutated PIK3CA. | 2014-02-27 |
20140056882 | TREATMENT OF PULMONARY DISEASE CONDITIONS - The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor. | 2014-02-27 |
20140056883 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY - The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. | 2014-02-27 |
20140056884 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY - The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. | 2014-02-27 |
20140056885 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY - The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. | 2014-02-27 |
20140056886 | Humanized Anti-IL-20 Antibody And Uses Thereof - Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure. | 2014-02-27 |
20140056887 | COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY - New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 2014-02-27 |
20140056888 | HIGH CONCENTRATION ANTIBODY FORMULATIONS - The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment. | 2014-02-27 |
20140056889 | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES - The invention provides methods and compositions for treating various autoimmune diseases (such as systemic lupus erythematousu) with an interferon inhibitor (such as an anti-intereron-alpha monoclonal antibody). More specifically, the invention provides a method of diagnosing, monitoring and adjusting the treatment of such a patient by way of an interferon signature metric (interferon response gene measurement value), a certain anti-dsDNA antibody titre or being ENA− (levels of extractable nuclear antigens lower than a healthy level). Furthermore, the invention provides articles of manufacture associated with such a diagnosis. | 2014-02-27 |
20140056890 | Binding Agents That Modulate the Hippo Pathway and Uses Thereof - The present invention relates to agents that modulate the Hippo pathway and Hippo pathway signaling, such as antibodies and soluble receptors, as well as to methods of using the agents for the treatment of diseases such as cancer. | 2014-02-27 |
20140056891 | TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS - The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation. | 2014-02-27 |
20140056892 | VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders - The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions. | 2014-02-27 |
20140056893 | Homodimeric Proteins - This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein. | 2014-02-27 |
20140056894 | RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS - The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signalling system during angiogenesis. The invention also relates to the use regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis. | 2014-02-27 |
20140056895 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 2014-02-27 |
20140056896 | ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 2014-02-27 |
20140056897 | BISPECIFIC THREE-CHAIN ANTIBODY-LIKE MOLECULES - The present invention relates to novel bispecific three-chain antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific three-chain antibody-like molecules (TCAs) capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases. | 2014-02-27 |
20140056898 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab. | 2014-02-27 |
20140056899 | ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 2014-02-27 |
20140056900 | METHOD FOR INHIBITING BINDING TO B-CELL RECEPTOR - The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprises: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i). | 2014-02-27 |
20140056901 | ANTI-TAU ANTIBODIES AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES - The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopathies (e.g. Alzheimer's disease). | 2014-02-27 |
20140056902 | PHARMACEUTICAL AGENT COMPRISING ANTI-BMP9 ANTIBODY AS ACTIVE INGREDIENT FOR TREATMENT OF ANEMIA SUCH AS RENAL ANEMIA AND CANCER ANEMIA - The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same. | 2014-02-27 |
20140056903 | HUMAN ANTIBODIES TO GFR ALPHA 3 AND METHODS OF USE THEREOF - The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFRα3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions. | 2014-02-27 |
20140056904 | Antibodies to TTR and Methods of Use - The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR. | 2014-02-27 |
20140056905 | ANTI-KIT ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein. | 2014-02-27 |
20140056906 | SECRETED PROTEINS - The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP. | 2014-02-27 |
20140056907 | ANTI-ASIC1 ANTIBODIES AND USES THEREOF - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders. | 2014-02-27 |
20140056908 | CLOSTEROVIRUS-BASED NUCLEIC ACID MOLECULES AND USES THEREOF - The present invention relates to novel nucleic acid molecules for producing target polypeptides in plant cells. More specifically, the novel nucleic acid molecules comprise a minireplicon derived from a Closteroviridae virus and heterologous polynucleotides encoding the target polypeptides. Also provided are compositions comprising the target polypeptides and uses thereof. | 2014-02-27 |
20140056909 | TREATING CANCER - This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided. | 2014-02-27 |